Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
64
TKPHF Quote, Financials, Valuation and Earnings
Last price:
$31.12
Seasonality move
:
1.43%
Day range:
$30.42 - $30.42
52-week range:
$24.94 - $32.13
Dividend yield:
4.36%
P/E ratio:
192.99x
P/S ratio:
1.64x
P/B ratio:
1.00x
Volume:
628.1K
Avg. volume:
134.5K
1-year change:
17.44%
Market cap:
$48B
Revenue:
$30.1B
EPS (TTM):
$0.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical Co., Ltd.
|
$7.6B | -- | -1.4% | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical Co., Ltd.
|
$30.42 | -- | $48B | 192.99x | $0.67 | 4.36% | 1.64x |
|
HLOSF
Healios KK
|
$2.10 | -- | $242.4M | -- | $0.00 | 0% | 329.74x |
|
PPTDF
PeptiDream Inc.
|
$10.75 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.58x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.15 | -- | $466M | -- | $0.00 | 0% | 2.41x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -1.309 | 67.93% | 0.64x |
|
HLOSF
Healios KK
|
47.23% | -0.711 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.120 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.139 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Takeda Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns TKPHF or HLOSF?
Healios KK has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical Co., Ltd.47.41% -$0.05 $79.7B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About TKPHF or HLOSF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is TKPHF or HLOSF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of -0.028, which suggesting that the stock is 102.755% less volatile than S&P 500. In comparison Healios KK has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.
-
Which is a Better Dividend Stock TKPHF or HLOSF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.67 per share corresponding to a yield of 4.36%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 286.72% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or HLOSF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than Healios KK quarterly revenues of $128.8K. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Healios KK's net income of $3.8M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 192.99x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.64x versus 329.74x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical Co., Ltd.1.64x 192.99x $7.5B -$79.5M HLOSFHealios KK329.74x -- $128.8K $3.8M
-
Which has Higher Returns TKPHF or PPTDF?
PeptiDream Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -25.38%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical Co., Ltd.47.41% -$0.05 $79.7B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About TKPHF or PPTDF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is TKPHF or PPTDF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of -0.028, which suggesting that the stock is 102.755% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.551, suggesting its less volatile than the S&P 500 by 44.854%.
-
Which is a Better Dividend Stock TKPHF or PPTDF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.67 per share corresponding to a yield of 4.36%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 286.72% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or PPTDF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than PeptiDream Inc.'s net income of -$7.4M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 192.99x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.64x versus 11.58x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical Co., Ltd.1.64x 192.99x $7.5B -$79.5M PPTDFPeptiDream Inc.11.58x 13.79x $29.3M -$7.4M
-
Which has Higher Returns TKPHF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -24.76%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical Co., Ltd.47.41% -$0.05 $79.7B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About TKPHF or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is TKPHF or SOLTF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of -0.028, which suggesting that the stock is 102.755% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.011, suggesting its less volatile than the S&P 500 by 98.941%.
-
Which is a Better Dividend Stock TKPHF or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.67 per share corresponding to a yield of 4.36%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 286.72% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or SOLTF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 192.99x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.64x versus 2.41x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical Co., Ltd.1.64x 192.99x $7.5B -$79.5M SOLTFNxera Pharma Co., Ltd.2.41x -- $45.8M -$11.3M
-
Which has Higher Returns TKPHF or STMM?
Stemcell Holdings, Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of --. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical Co., Ltd.47.41% -$0.05 $79.7B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About TKPHF or STMM?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is TKPHF or STMM More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of -0.028, which suggesting that the stock is 102.755% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TKPHF or STMM?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.67 per share corresponding to a yield of 4.36%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 286.72% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or STMM?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 192.99x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.64x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical Co., Ltd.1.64x 192.99x $7.5B -$79.5M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is down 2.6% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 8.05% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is down 0.02% over the past day.
